Un nouvel inhibiteur de tyrosine kinase

Hagop M. Kantarjian, Francis Giles, Norbert Gattermann, Kapil Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O'Brien, Mark Litzow, Ravi Bhatia, Francisco Cervantes, Ariful Haque, Yaping Shou, Debra J. Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood. ,vol. 110, pp. 3540- 3546 ,(2007) , 10.1182/BLOOD-2007-03-080689

Pavinder Kaur, Niklas Feldhahn, Bin Zhang, Daniel Trageser, Markus Müschen, Veerle Pertz, John Groffen, Nora Heisterkamp, Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia. Molecular Cancer. ,vol. 6, pp. 67- 67 ,(2007) , 10.1186/1476-4598-6-67

Hm Kantaijian, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood. ,vol. 110, pp. 3540- 3546 ,(2007)